GOSS · Gossamer Bio, Inc. · Webcasts, Transcripts & Audio
$11.50
+0.07 (+0.61%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Nov 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company has concluded that these circumstances and the uncertainties associated with the Company’s ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 10, 2026
Market Cap
$68.69M
Shares
6.12M
Volume · Nov 19
143.82K
Avg daily vol (50 sessions)
251.05K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Gossamer Bio, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Gossamer Bio, Inc. (GOSS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-07-27
Gossamer Bio, Inc. (GOSS) Q2 2026 Earnings Call Transcript
Confident tone
Saralutinib clinical evidence
FDA regulatory path and NDA submission
PHILD indication expansion
Revenue
$9.24M
▼ 19.6% YoY Diluted EPS
$-6.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-18
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript
Positive tone
CT-FRI sub-study and reverse remodeling
Procera Phase III results and clinical signal
Unmet need in PAH and community support
Revenue
$16.95M
▲ 71.5% YoY Diluted EPS
$-16.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Call Transcript
Confident tone
Seralutinib commercial opportunity
PROSERA Phase III enrollment
Competitive landscape (sotatercept, Tyvaso)
Revenue
$9.89M
Diluted EPS
$-12.80
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Gossamer Bio, Inc. (GOSS) Q2 2023 Earnings Call
Revenue
$0
Diluted EPS
$-36.00
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Gossamer Bio, Inc. (GOSS) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Gossamer Bio, Inc. (GOSS) Q3 2021 Earnings Call Transcript
Diluted EPS
$-64.00
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Gossamer Bio, Inc. (GOSS) Q2 2021 Earnings Call Transcript
Diluted EPS
$-64.00
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Gossamer Bio, Inc. (GOSS) Q1 2021 Earnings Call
Diluted EPS
$-62.40
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Gossamer Bio, Inc. (GOSS) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Gossamer Bio, Inc. (GOSS) Q3 2020 Earnings Call Transcript
Diluted EPS
$-64.00
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Gossamer Bio, Inc. (GOSS) Q1 2020 Earnings Call Transcript
Diluted EPS
$-69.60
Audio
Transcript
Slides
8-K10-Q
Showing 1–11 of 11 webcasts
Key facts
CIK
1728117
CUSIP
38341P201
13F (30d)
100 filings
75 filers
Visit website
Investor relations